En­her­tu picks up an­oth­er win for As­traZeneca and Dai­ichi Sankyo, join­ing the pri­or­i­ty re­view lane for gas­tric can­cer

Five months af­ter En­her­tu re­ceived twin break­through ther­a­py des­ig­na­tions, As­traZeneca and Dai­ichi Sankyo are one step clos­er to nab­bing an­oth­er ap­proval for their po­ten­tial …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER